2010 年伯克霍尔德菌和鼻疽伯克霍尔德菌感染治疗和接触后预防研讨会报告
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.
出版信息
Emerg Infect Dis. 2012 Dec;18(12):e2. doi: 10.3201/eid1812.120638.
Abstract
The US Public Health Emergency Medical Countermeasures Enterprise convened subject matter experts at the 2010 HHS Burkholderia Workshop to develop consensus recommendations for postexposure prophylaxis against and treatment for Burkholderia pseudomallei and B. mallei infections, which cause melioidosis and glanders, respectively. Drugs recommended by consensus of the participants are ceftazidime or meropenem for initial intensive therapy, and trimethoprim/sulfamethoxazole or amoxicillin/clavulanic acid for eradication therapy. For postexposure prophylaxis, recommended drugs are trimethoprim/sulfamethoxazole or co-amoxiclav. To improve the timely diagnosis of melioidosis and glanders, further development and wide distribution of rapid diagnostic assays were also recommended. Standardized animal models and B. pseudomallei strains are needed for further development of therapeutic options. Training for laboratory technicians and physicians would facilitate better diagnosis and treatment options.
摘要
美国公共卫生应急医疗对策企业召集了专题专家参加 2010 年 HHS 伯克霍尔德菌研讨会，以制定针对布氏杆菌假单胞菌和马鼻疽伯克霍尔德菌感染（分别导致类鼻疽和鼻疽）的暴露后预防和治疗的共识建议。经与会者协商一致推荐的药物为头孢他啶或美罗培南作为初始强化治疗，以及复方磺胺甲噁唑或阿莫西林/克拉维酸用于清除治疗。对于暴露后预防，推荐的药物为复方磺胺甲噁唑或复方阿莫西林。为了提高类鼻疽和鼻疽的及时诊断，还建议进一步开发和广泛分发快速诊断检测方法。需要标准化的动物模型和布氏杆菌假单胞菌菌株，以进一步开发治疗选择。对实验室技术人员和医生进行培训将有助于更好地诊断和治疗选择。
相似文献
1
Workshop on treatment of and postexposure prophylaxis for Burkholderia pseudomallei and B. mallei Infection, 2010.
Emerg Infect Dis. 2012 Dec;18(12):e2. doi: 10.3201/eid1812.120638.
2
Trimethoprim/sulfamethoxazole (co-trimoxazole) prophylaxis is effective against acute murine inhalational melioidosis and glanders.
Int J Antimicrob Agents. 2013 Jun;41(6):552-7. doi: 10.1016/j.ijantimicag.2013.02.007. Epub 2013 Mar 19.
3
Burkholderia mallei and Burkholderia pseudomallei: the causative micro-organisms of glanders and melioidosis.
Recent Pat Antiinfect Drug Discov. 2007 Nov;2(3):233-41. doi: 10.2174/157489107782497335.
4
Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.
PLoS One. 2015 Jul 6;10(7):e0132032. doi: 10.1371/journal.pone.0132032. eCollection 2015.
5
Pathogenesis of Burkholderia pseudomallei and Burkholderia mallei.
Mil Med. 2009 Jun;174(6):647-51.
6
Protective efficacy of heat-inactivated B. thailandensis, B. mallei or B. pseudomallei against experimental melioidosis and glanders.
Vaccine. 2009 Jul 16;27(33):4447-51. doi: 10.1016/j.vaccine.2009.05.040. Epub 2009 May 31.
7
Antibodies against -Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.
Infect Immun. 2017 Jul 19;85(8). doi: 10.1128/IAI.00102-17. Print 2017 Aug.
8
Development of Burkholderia mallei and pseudomallei vaccines.
Front Cell Infect Microbiol. 2013 Mar 11;3:10. doi: 10.3389/fcimb.2013.00010. eCollection 2013.
9
Clinical guideline for diagnosis and management of melioidosis.
Rev Inst Med Trop Sao Paulo. 2006 Jan-Feb;48(1):1-4. doi: 10.1590/s0036-46652006000100001. Epub 2006 Mar 9.
10
Melioidosis acquired by traveler to Nigeria.
Emerg Infect Dis. 2011 Jul;17(7):1296-8. doi: 10.3201/eid1707.100502.
引用本文的文献
1
Chronic cutaneous melioidosis with concomitant basal cell carcinoma.
IDCases. 2025 May 9;41:e02255. doi: 10.1016/j.idcr.2025.e02255. eCollection 2025.
2
Postexposure Antimicrobial Drug Therapy in Goats Infected with Burkholderia pseudomallei.
Emerg Infect Dis. 2025 May;31(5):967-975. doi: 10.3201/eid3105.241274.
3
Rare or Unusual Non-Fermenting Gram-Negative Bacteria: Therapeutic Approach and Antibiotic Treatment Options.
Antibiotics (Basel). 2025 Mar 16;14(3):306. doi: 10.3390/antibiotics14030306.
4
Performance of Antibody-Detection Tests for Human Melioidosis: A Systematic Review and Meta-analysis.
Malays J Med Sci. 2024 Dec;31(6):34-56. doi: 10.21315/mjms2024.31.6.4. Epub 2024 Dec 31.
5
Multi-systemic melioidosis.
World J Clin Cases. 2024 Oct 6;12(28):6151-6154. doi: 10.12998/wjcc.v12.i28.6151.
6
Pyrexia of Unknown Origin in a Young Male: Unmasking Melioidosis in a Tuberculosis-Endemic Setting.
Cureus. 2024 Jul 7;16(7):e64024. doi: 10.7759/cureus.64024. eCollection 2024 Jul.
7
Isolation, serological and molecular methods in screening of in East Azerbaijan province, Iran.
Vet Res Forum. 2024;15(5):231-236. doi: 10.30466/vrf.2024.2010651.4002. Epub 2024 May 15.
8
Patient Presenting with Abscess Unresponsive to Treatment and Progressive to Osteomyelitis: A Rare Cause .
Sisli Etfal Hastan Tip Bul. 2024 Jun 28;58(2):258-261. doi: 10.14744/SEMB.2023.70194. eCollection 2024.
9
Multi-systemic melioidosis in a patient with type 2 diabetes in non-endemic areas: A case report and review of literature.
World J Clin Cases. 2024 Mar 26;12(9):1669-1676. doi: 10.12998/wjcc.v12.i9.1669.
10
Impact of template denaturation prior to whole genome amplification on gene detection in high GC-content species, Burkholderia mallei and B. pseudomallei.
BMC Res Notes. 2024 Mar 12;17(1):70. doi: 10.1186/s13104-024-06717-8.
本文引用的文献
1
Antimicrobial resistance to ceftazidime involving loss of penicillin-binding protein 3 in Burkholderia pseudomallei.
Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17165-70. doi: 10.1073/pnas.1111020108. Epub 2011 Oct 3.
2
Evaluation of surrogate animal models of melioidosis.
Front Microbiol. 2010 Dec 29;1:141. doi: 10.3389/fmicb.2010.00141. eCollection 2010.
3
Molecular Investigations of PenA-mediated β-lactam Resistance in Burkholderia pseudomallei.
Front Microbiol. 2011 Jul 1;2:139. doi: 10.3389/fmicb.2011.00139. eCollection 2011.
4
Comparative in vitro susceptibility of Burkholderia pseudomallei to doripenem, ertapenem, tigecycline and moxifloxacin.
Int J Antimicrob Agents. 2011 Jun;37(6):547-9. doi: 10.1016/j.ijantimicag.2011.02.001. Epub 2011 Apr 9.
5
The epidemiology and clinical spectrum of melioidosis: 540 cases from the 20 year Darwin prospective study.
PLoS Negl Trop Dis. 2010 Nov 30;4(11):e900. doi: 10.1371/journal.pntd.0000900.
6
BurkDiff: a real-time PCR allelic discrimination assay for Burkholderia pseudomallei and B. mallei.
PLoS One. 2010 Nov 12;5(11):e15413. doi: 10.1371/journal.pone.0015413.
7
Defining the true sensitivity of culture for the diagnosis of melioidosis using Bayesian latent class models.
PLoS One. 2010 Aug 30;5(8):e12485. doi: 10.1371/journal.pone.0012485.
8
Molecular basis of rare aminoglycoside susceptibility and pathogenesis of Burkholderia pseudomallei clinical isolates from Thailand.
PLoS Negl Trop Dis. 2009 Sep 22;3(9):e519. doi: 10.1371/journal.pntd.0000519.
9
Molecular identification and typing of Burkholderia pseudomallei and Burkholderia mallei: when is enough enough?
Trans R Soc Trop Med Hyg. 2008 Dec;102 Suppl 1:S134-9. doi: 10.1016/S0035-9203(08)70030-0.
10
Maternal exposure to folic acid antagonists and placenta-mediated adverse pregnancy outcomes.
CMAJ. 2008 Dec 2;179(12):1263-8. doi: 10.1503/cmaj.080859.
Zotero 插件